Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Excedrin Migraine studies

This article was originally published in The Tan Sheet

Executive Summary

Excedrin Migraine studies: Patients taking the acetaminophen (250 mg), aspirin (250 mg) and caffeine (65 mg) combination OTC analgesic experienced "significant" relief of migraine-associated pain within 30 minutes of dosing in a pooled analysis of three double-blind, randomized, placebo-controlled trials, Richard Lipton, MD, Albert Einstein College of Medicine, et al., report in the February issue of the Archives of Neurology. Patients also noticed "significant improvements in ability to perform usual activities at one hour after dose and at all time points thereafter," the researchers note. Data from the trials were used by Bristol-Myers Squibb to gain FDA approval of the first OTC migraine indication ("The Tan Sheet" Jan. 19, p. 1). BMS presented the data at a meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees July 15 ("The Tan Sheet" July 21, 1997, pp. 8-12)...

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts